<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><description>姓药的来说药，带你进入最深层次的医药领域，把握医药动态，了解最新前沿！</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 27 May 2021 07:32:52 +0800</pubDate><image><url>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</url><title>小药说药 | wechat-feeds</title><link>http://MzAxMDMyMTQwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>FDA发布双特异性抗体研发指南</title><link>https://mp.weixin.qq.com/s/nJmbi1F12f7kpHGMq_t3HA</link><description></description><content:encoded><![CDATA[FDA发布双特异性抗体研发指南]]></content:encoded><pubDate>Thu, 27 May 2021 06:29:48 +0800</pubDate></item><item><title>中国生物药研发现状与未来</title><link>https://mp.weixin.qq.com/s/utqalrdRLVgYMDQpg2Tk-w</link><description></description><content:encoded><![CDATA[中国生物药研发现状与未来]]></content:encoded><pubDate>Wed, 26 May 2021 06:32:42 +0800</pubDate></item><item><title>2020细胞免疫疗法研究报告</title><link>https://mp.weixin.qq.com/s/UVPmOHnzOOuALdsCnfEw2A</link><description></description><content:encoded><![CDATA[2020细胞免疫疗法研究报告]]></content:encoded><pubDate>Tue, 25 May 2021 06:20:07 +0800</pubDate></item><item><title>Trastuzumab Deruxtecan: HER-2+实体瘤治疗的变革者</title><link>https://mp.weixin.qq.com/s/JJNDU0IeYg23HCXZeIeXzQ</link><description></description><content:encoded><![CDATA[Trastuzumab Deruxtecan: HER-2+实体瘤治疗的变革者]]></content:encoded><pubDate>Mon, 24 May 2021 06:45:49 +0800</pubDate></item><item><title>君实生物：一个被低估的企业</title><link>https://mp.weixin.qq.com/s/qaOXScltfCzvYw-km6hcCg</link><description></description><content:encoded><![CDATA[君实生物：一个被低估的企业]]></content:encoded><pubDate>Sun, 23 May 2021 06:31:02 +0800</pubDate></item><item><title>TACA靶向治疗进展：CAR-T和双抗</title><link>https://mp.weixin.qq.com/s/gzQK2DiQ_mpgNd8edBNHAw</link><description></description><content:encoded><![CDATA[TACA靶向治疗进展：CAR-T和双抗]]></content:encoded><pubDate>Sat, 22 May 2021 06:33:18 +0800</pubDate></item><item><title>ASCO2021前瞻：肿瘤免疫专场的中国风</title><link>https://mp.weixin.qq.com/s/OjOoo5B8oZ6wNpBXwG-s4w</link><description></description><content:encoded><![CDATA[ASCO2021前瞻：肿瘤免疫专场的中国风]]></content:encoded><pubDate>Fri, 21 May 2021 06:07:22 +0800</pubDate></item><item><title>首次证明无ADCC效应CTLA4抗体临床OS获益</title><link>https://mp.weixin.qq.com/s/9hJqNya6d9n7fO4FgeL5_A</link><description></description><content:encoded><![CDATA[首次证明无ADCC效应CTLA4抗体临床OS获益]]></content:encoded><pubDate>Fri, 21 May 2021 06:07:22 +0800</pubDate></item><item><title>Apexigen公布CD40抗体治疗胰腺癌一年生存期临床获益结果，形势不佳</title><link>https://mp.weixin.qq.com/s/4b0QXGWj1rEYXTsbIeAxIA</link><description></description><content:encoded><![CDATA[Apexigen公布CD40抗体治疗胰腺癌一年生存期临床获益结果，形势不佳]]></content:encoded><pubDate>Fri, 21 May 2021 06:07:22 +0800</pubDate></item><item><title>KRAS靶点的前世今生</title><link>https://mp.weixin.qq.com/s/z14pS7sKKcOGMrOytJkKhg</link><description></description><content:encoded><![CDATA[KRAS靶点的前世今生]]></content:encoded><pubDate>Thu, 20 May 2021 06:30:39 +0800</pubDate></item><item><title>与HER2的天壤之别？HER3究竟能否成药！</title><link>https://mp.weixin.qq.com/s/17rnMCPExfszkAThgI5nmg</link><description></description><content:encoded><![CDATA[与HER2的天壤之别？HER3究竟能否成药！]]></content:encoded><pubDate>Wed, 19 May 2021 06:40:28 +0800</pubDate></item><item><title>多肽类药物发展历程与市场简述</title><link>https://mp.weixin.qq.com/s/OXMWwnYMuJfXPFw9N6JC2w</link><description></description><content:encoded><![CDATA[多肽类药物发展历程与市场简述]]></content:encoded><pubDate>Tue, 18 May 2021 06:32:53 +0800</pubDate></item></channel></rss>